[Skip to Content]

Claim CME

Neonatology

Can We Protect Pregnant Women and Young Infants From COVID-19 Through Maternal Immunization?

Educational Objective
To identify the key insights or developments described in this article

1 Credit CME

JAMA Pediatrics

Published Online: January 29, 2021

Editorial

Article Information and Disclosures

Flor M. Munoz, MD¹

Author Affiliations

¹Section of Infectious Diseases, Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas

Read article on JAMA Network

Read Article Claim CME

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy and early infancy can result in severe disease.¹^- 3 Less is known about the immune responses of pregnant women with coronavirus disease 2019 (COVID-19) and the possibility for infant protection. Vaccination of pregnant women with SARS-CoV-2 vaccines in development has begun in the United States in the context of emergency use authorized vaccine deployment for high-risk priority groups and guidance from the US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices and the American College of Obstetrics and Gynecology.⁴^- 8 Therefore, it is imperative to better understand the potential of immunization during pregnancy for maternal and infant disease prevention and for the implementation of pandemic control strategies.

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Corresponding Author: Flor M. Munoz, MD, Section of Infectious Diseases, Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, BCM-280, Houston, TX 77030 (florm@bcm.edu).

Published Online: January 29, 2021. doi:10.1001/jamapediatrics.2021.0043

Conflict of Interest Disclosures: Dr Munoz reported serving on the data and safety monitoring boards of Moderna, Pfizer, Virometix, and Meissa Vaccines and grants from Novavax Research and Gilead Research outside the submitted work.

References

Allotey J , Stallings E , Bonet M , et al; for PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi:10.1136/bmj.m3320 PubMed Google Scholar Crossref

Zambrano LD , Ellington S , Strid P , et al; CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641-1647. doi:10.15585/mmwr.mm6944e3 PubMed Google Scholar Crossref

Woodworth KR , Olsen EO , Neelam V , et al; CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team; COVID-19 Pregnancy and Infant Linked Outcomes Team (PILOT). Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy: SET-NET, 16 jurisdictions, March 29-October 14, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1635-1640. doi:10.15585/mmwr.mm6944e2 PubMed Google Scholar Crossref

US Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine. Updated January 12, 2021. Accessed January 13, 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine

US Food and Drug Administration. Moderna COVID-19 vaccine. Updated January 6, 2021. Accessed January 13, 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine

Centers for Disease Control and Prevention. COVID-19 ACIP vaccine recommendations. Updated December 22, 2020. Accessed January 13, 2021. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html

Dooling K , Marin M , Wallace M , et al. The Advisory Committee on Immunization Practices’ updated interim recommendations for allocation of COVID-19 vaccine: United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1657-1660. doi:10.15585/mmwr.mm695152e2 PubMed Google Scholar Crossref

American College of Obstetricians and Gynecologists. Vaccinating pregnant and lactating patients against COVID-19. Published December 2020. Accessed January 13, 2021. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19

Flannery DD , Gouma S , Dhudasia MB , et al. Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. JAMA Pediatr. Published online January 29, 2021. doi:10.1001/jamapediatrics.2021.0038 Google Scholar

Madhi SA , Polack FP , Piedra PA , et al; Prepare Study Group. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020;383(5):426-439. doi:10.1056/NEJMoa1908380 PubMed Google Scholar Crossref

Edlow AG , Li JZ , Collier AY , et al. Assessment of maternal and neonatal SARS-CoV-2 viral load, transplacental antibody transfer, and placental pathology in pregnancies during the COVID-19 pandemic. JAMA Netw Open. 2020;3(12):e2030455. doi:10.1001/jamanetworkopen.2020.30455 PubMed Google Scholar

Toner LE , Gelber SE , Pena JA , Fox NS , Rebarber A . A case report to assess passive immunity in a COVID positive pregnant patient. Am J Perinatol. 2020;37(12):1280-1282. doi:10.1055/s-0040-1715643 PubMed Google Scholar Crossref

Cavaliere AF , Marchi L , Aquilini D , Brunelli T , Vasarri PL . Passive immunity in newborn from SARS-CoV-2-infected mother. J Med Virol. 2020;1-4. doi:10.1002/jmv.26609 PubMed Google Scholar

Bwire GM , Njiro BJ , Mwakawanga DL , Sabas D , Sunguya BF . Possible vertical transmission and antibodies against SARS-CoV-2 among infants born to mothers with COVID-19: a living systematic review. J Med Virol. 2020;1-9. doi:10.1002/jmv.26622 PubMed Google Scholar

Cohen SA , Kellogg C , Equils O . Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development. Hum Vaccin Immunother. 2020;1-4. doi:10.1080/21645515.2020.1787074 PubMed Google Scholar

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.